NASDAQ:AKCA

Akcea Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$18.17
0.00 (0.00 %)
(As of 10/12/2020)
Add
Compare
Today's Range
$18.17
$18.17
50-Day Range
$18.13
$18.17
52-Week Range
$8.00
$21.70
VolumeN/A
Average Volume361,806 shs
Market Capitalization$1.85 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.45

Receive AKCA News and Ratings via Email

Sign-up to receive the latest news and ratings for Akcea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Akcea Therapeutics logo

About Akcea Therapeutics

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.68 out of 5 stars

Medical Sector

1342nd out of 2,100 stocks

Pharmaceutical Preparations Industry

605th out of 832 stocks

Analyst Opinion: 1.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions

Is Akcea Therapeutics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Akcea Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AKCA, but not buy additional shares or sell existing shares.
View analyst ratings for Akcea Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Akcea Therapeutics?

Wall Street analysts have given Akcea Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Akcea Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Akcea Therapeutics' earnings last quarter?

Akcea Therapeutics, Inc. (NASDAQ:AKCA) issued its earnings results on Tuesday, August, 4th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.14. The company earned $22.38 million during the quarter, compared to analysts' expectations of $30.93 million. Akcea Therapeutics had a negative net margin of 12.34% and a negative trailing twelve-month return on equity of 8.94%. The company's revenue for the quarter was down 15.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.40) earnings per share.
View Akcea Therapeutics' earnings history
.

What price target have analysts set for AKCA?

3 brokers have issued twelve-month target prices for Akcea Therapeutics' shares. Their forecasts range from $18.15 to $18.15. On average, they anticipate Akcea Therapeutics' share price to reach $18.15 in the next twelve months. This suggests that the stock has a possible downside of 0.1%.
View analysts' price targets for Akcea Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Akcea Therapeutics' key executives?

Akcea Therapeutics' management team includes the following people:
  • Ms. Paula Soteropoulos, CEO & Director (Age 51)
  • Mr. Michael F. MacLean, Chief Financial Officer (Age 53)
  • Dr. Louis St. Laurence O'Dea FRCPC, MB, BCh, BAO, FRCP(C), Chief Medical Officer (Age 68)
  • Ms. Sarah Boyce, Pres & Director (Age 47)
  • Mr. Jeffrey M. Goldberg, Chief Operating Officer (Age 46)

Who are some of Akcea Therapeutics' key competitors?

What other stocks do shareholders of Akcea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Achaogen (AKAO), Ciena (CIEN), AMC Entertainment (AMC), Advanced Micro Devices (AMD), Apollo Global Management (APO) and Exelixis (EXEL).

When did Akcea Therapeutics IPO?

(AKCA) raised $125 million in an initial public offering on Friday, July 14th 2017. The company issued 9,600,000 shares at $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.

What is Akcea Therapeutics' stock symbol?

Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."

What is Akcea Therapeutics' stock price today?

One share of AKCA stock can currently be purchased for approximately $18.17.

How much money does Akcea Therapeutics make?

Akcea Therapeutics has a market capitalization of $1.85 billion and generates $488.54 million in revenue each year. The company earns $40.77 million in net income (profit) each year or $0.48 on an earnings per share basis.

How many employees does Akcea Therapeutics have?

Akcea Therapeutics employs 248 workers across the globe.

What is Akcea Therapeutics' official website?

The official website for Akcea Therapeutics is www.akceatx.com.

Where are Akcea Therapeutics' headquarters?

Akcea Therapeutics is headquartered at 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210.

How can I contact Akcea Therapeutics?

Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected]


This page was last updated on 6/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.